You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

248 Results
Regimen
Intent: Palliative
May 2019
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Curative, Adjuvant
Jan 2019
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Adjuvant, Curative
May 2019
Regimen
Cancer Type:
Endocrine, 
Thyroid
Intent: Palliative
May 2019
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Intent: Palliative
Funding:
ODB - General Benefit
    megestrol - oral tablets
ODB - General Benefit
    tamoxifen
May 2019
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Neoadjuvant, Adjuvant
May 2019
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
May 2019
Regimen
Cancer Type:
Lung, 
Mesothelioma (Pleural)
Intent: Palliative
May 2019
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - In Combination with Chemotherapy for Refractory Follicular Lymphoma
ODB - General Benefit
    prednisone
May 2019
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - Maintenance Treatment for Refractory Follicular Lymphoma
Dec 2019
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - In Combination with Chemotherapy for Refractory Follicular Lymphoma
ODB - General Benefit
    prednisone
ODB - General Benefit
    cyclophosphamide - oral tablets
May 2019
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - In Combination with Chemotherapy for Refractory Follicular Lymphoma
ODB - General Benefit
    cyclophosphamide - oral tablets
May 2019

Pages